pharmaphorum
FEBRUARY 11, 2021
Shares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s disease (AD) hit the mark in a phase 1/2 trial. . ACI-35.030, partnered with Johnson & Johnson, is designed to stimulate the body to generate antibodies against tau protein, one of the factors though to play a role in the development of AD dementia.
Pharma Times
FEBRUARY 10, 2021
Trial is sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
FEBRUARY 11, 2021
Are you tired of having to naviagate complicated contracts to access the information you need? Let DrugPatentWatch free you from weeks of negotiating complex contracts and let you focus on…. The post Say ‘NO’ to bad contracts appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
FEBRUARY 10, 2021
In a clinical trial, participants taking semaglutide lost 15 percent of their body weight, on average.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
FEBRUARY 12, 2021
The life sciences industry has an important role in the Irish economy, with sectors such as biologics booming across the country. Rory Mullen, head of biopharma at Ireland’s economic development agency IDA Ireland tells pharmaphorum why business is blossoming in the Emerald Isle. With an attractive corporate tax rate and the youngest workforce in the EU, Ireland continues to be a popular destination for life science companies to settle.
Pharma Times
FEBRUARY 8, 2021
Jazz will add GW's plant-derived cannabinoid treatment Epidiolex to its roster
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
FEBRUARY 7, 2021
Officials are racing to vaccinate as many people as possible in order to outpace more contagious variants of the virus that were first identified in Britain and South Africa.
pharmaphorum
FEBRUARY 9, 2021
The UK government’s massive spending on the coronavirus pandemic response has been “rife with conflicts of interest”, says the opposition Labour Party, and an independent watchdog should be set up to oversee procurement contracts. That was the message delivered by shadow Cabinet Office minister Rachel Reeves in a speech yesterday which claimed almost £2 billion of the £23.1 billion public sector spend on the pandemic went on contracts that were awarded to “Conservative friends and donors”
Pharma Times
FEBRUARY 9, 2021
Charity has urged the UK government to provide clarity on whether people receiving antibiotics can receive a COVID-19 vaccination
Outsourcing Pharma
FEBRUARY 9, 2021
The federal agency continues to keep researchers, pharma firms and citizens apprised of current happenings and research related to the virus and pandemic.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
FEBRUARY 9, 2021
Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
pharmaphorum
FEBRUARY 11, 2021
Rob Wood has acquired a large minority stake in performance-io through a multimillion-pound deal that will see him join the specialist online performance marketing agency’s executive board. A former AstraZeneca director, Wood founded commercial and medical benchmarking firm STEM in 2007 before selling it to UDG Healthcare for £84 million in 2016. Since leaving that company he has invested in a number of disruptive technology-driven pharma service providers. performance-io ’s founder and CEO Matt
Pharma Times
FEBRUARY 12, 2021
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
Eye on FDA
FEBRUARY 10, 2021
Last month we looked at a review of FDA press releases for last year and as one might have expected, there was an enormous spike in communications as a result of the COVID-19 pandemic. Looking now to a review of enforcement by the Office of Prescription Drug Promotion (OPDP) in 2020, we see a different picture. We instead see the same pace as we have the past several years – that is anemic levels of enforcement.
NY Times
FEBRUARY 10, 2021
Pharmacies are dangling five-figure signing bonuses and competing against one another to quickly recruit pharmacists and support staff.
pharmaphorum
FEBRUARY 10, 2021
Improving the Safety, Efficacy & Predictability of Monotherapy & Combinatorial Therapies to Fast-track the Discovery & Development of TNBC Treatments to Reach Patients in Need. This is the primary industry platform specifically dedicated to providing you insight into the latest developments of safe and efficacious blockbuster therapies to treat triple negative breast cancer.
Pharma Times
FEBRUARY 12, 2021
NICE determined that there were uncertainties around the cost-effectiveness of the therapy
Outsourcing Pharma
FEBRUARY 9, 2021
The collaboration between the Jameel Clinic and pharma firm will harness artificial intelligence and machine learning in developing health solutions.
NY Times
FEBRUARY 12, 2021
Federal regulators are in favor of a simple, potentially quick fix to bolster coronavirus vaccine supplies: more doses per bottle.
pharmaphorum
FEBRUARY 10, 2021
Don’t panic – that’s the message from one ABPI code expert who tells Amanda Barrell it’s time to take stock and prioritise. Compliance managers have less than six months to rewrite processes and procedures in line with the updated ABPI code of practice before it becomes enforceable in July. But it doesn’t all have to be done at once, says Dr Rina Newton, managing director at code consultancy firm, CompliMed.
Pharma Times
FEBRUARY 9, 2021
The Patient Partnership Index 2021 provides a unique opportunity for UK and global pharmaceutical companies to showcase, benchmark and measure the quality and impact of their advocacy with patient groups
Outsourcing Pharma
FEBRUARY 11, 2021
The global professional services firm has signed on the newest partner in the collaboration, aimed toward promoting innovation in pharma manufacturing.
NY Times
FEBRUARY 10, 2021
In a clinical trial, participants taking semaglutide lost 15 percent of their body weight, on average.
pharmaphorum
FEBRUARY 12, 2021
Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise. . The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets around the world and had sales of around $140 million last year.
Pharma Times
FEBRUARY 9, 2021
The research forms part of the CVD-COVID-UK flagship project consortium
Drug Patent Watch
FEBRUARY 12, 2021
Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are fifteen…. The post New patent for Vanda Pharms drug HETLIOZ appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
FEBRUARY 8, 2021
Europe’s collective vaccine purchase is an experiment in deeper integration. Despite a rocky start, many countries still stand to benefit, but it’s the most powerful who have least to gain.
pharmaphorum
FEBRUARY 8, 2021
In the third part of this series taking stock of t he 2019 Voluntary Scheme for Branded Medicines Pricing and Access objectives, Leela Barham looks at the third VPAS objective that relates to the economy and innovation. The objectives for the economy and innovation are to: deliver a net benefit to the UK economy overall; and. support the life sciences industry across the UK and future innovation.
Pharma Times
FEBRUARY 10, 2021
The CF STORM trial will seek to address how the treatment burden for people with CF can be reduced
Pharma Mirror
FEBRUARY 12, 2021
The Walden Group is pleased to announce the appointment of Dennis Spamer (38) as member of the Board authorized to sign as statutory director of the company. Together with Thomas Creuzberger, who has been managing Movianto Germany since more than 20 years and Stéphane Baudry, founder and CEO of the Walden Group, Spamer shall push on the further development of the logistics specialist.
NY Times
FEBRUARY 10, 2021
After ending its own Covid-19 vaccine trials, the company said that it is actively discussing with governments how to help its competitors make their shots.
pharmaphorum
FEBRUARY 8, 2021
Bristol-Myers Squibb finally has FDA approval for its CAR-T therapy liso-cel, which has been cleared by the US regulator as Breyanzi for certain forms of large B-cell lymphoma. The green light comes too late for holders of the contingent value right (CVR) BMS offered as a sweetener to its takeover of Celgene, which lapsed because liso-cel didn’t get approval by the deadline of 31 December.
Pharma Times
FEBRUARY 10, 2021
First immunotherapy indicated for certain BCC patients
Drug Patent Watch
FEBRUARY 11, 2021
Annual Drug Patent Expirations for ENJUVIA Enjuvia is a drug marketed by Aspen and is included in one NDA. There are two patents protecting this drug. This drug has seventeen…. The post New patent expiration for ASPEN drug ENJUVIA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
FEBRUARY 12, 2021
Federal regulators are in favor of a simple, potentially quick fix to bolster coronavirus vaccine supplies: more doses per bottle.
Expert insights. Personalized for you.
127 
Let's personalize your content